{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:25:15Z","timestamp":1792221915749,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.lungcan.2012.12.005","type":"journal-article","created":{"date-parts":[[2012,12,25]],"date-time":"2012-12-25T19:34:17Z","timestamp":1356464057000},"page":"307-311","source":"Crossref","is-referenced-by-count":20,"title":["A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation"],"prefix":"10.1016","volume":"79","clinical-trial-number":[{"clinical-trial-number":"nct00585377","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wallace","family":"Akerley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle","family":"Egbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graydon","family":"Harker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bylund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Van Duren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakravarthy","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.12.005_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer Statistics 2007","volume":"57","author":"Thun","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.lungcan.2012.12.005_bib0010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2012.12.005_bib0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.1988.6.4.633","article-title":"Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer?report of a Canadian multicenter randomized trial","volume":"6","author":"Rapp","year":"1988","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2012.12.005_bib0020","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lungcan.2012.12.005_bib0030","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"issue":"August (8)","key":"10.1016\/j.lungcan.2012.12.005_bib0035","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/JTO.0b013e3180cc2599","article-title":"Differences in primary care clinicians? approach to non-small cell lung cancer patients compared with breast cancer","volume":"2","author":"Wassenaar","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"July (2)","key":"10.1016\/j.lungcan.2012.12.005_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lungcan.2012.12.005_bib0045","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lungcan.2012.12.005_bib0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0055","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for Non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.lungcan.2012.12.005_bib0060","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"October (30)","key":"10.1016\/j.lungcan.2012.12.005_bib0065","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1200\/JCO.2007.12.3026","article-title":"Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer","volume":"25","author":"Herbst","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0070","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-08-2407","article-title":"Erlotinib and bevacizumab have synergistic activity against melanoma","volume":"15","author":"Schicher","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-06-0416","article-title":"Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade","volume":"6","author":"Wu","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"May (9780)","key":"10.1016\/j.lungcan.2012.12.005_bib0080","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/jnci\/djk195","article-title":"Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study","volume":"99","author":"Taguchi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0090","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/JTO.0b013e31826c1155","article-title":"Prognostic and predictive role of the Veristrat Plasma Test in patients with advanced non-small cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 Trial","volume":"7","author":"Carbone","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2012.12.005_bib0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI"},{"issue":"February (2)","key":"10.1016\/j.lungcan.2012.12.005_bib0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JTO.0b013e3181943bb9","article-title":"A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer","volume":"4","author":"Akerley","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.lungcan.2012.12.005_bib0105","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0110","first-page":"15s","article-title":"TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0115","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.7508","article-title":"International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer: The TORCH trial","volume":"28","author":"Gridelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.12.005_bib0120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lungcan.2009.11.019","article-title":"VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab","volume":"69","author":"Carbone","year":"2010","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2012.12.005_bib0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/JTO.0b013e3181c8cbd9","article-title":"Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503","volume":"5","author":"Amann","year":"2010","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212006502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212006502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T21:55:11Z","timestamp":1539986111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212006502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0169500212006502"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.12.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}